A 17-year-old Japanese girl visited our hospital for an evaluation of exertional dyspnea. A diagnosis of pulmonary arterial hypertension (PAH) was confirmed based on the findings of right heart catheterization. Detailed questioning revealed a family history of hereditary hemorrhagic telangiectasia (HHT), and a genetic mutation analysis disclosed a mutation in the activin receptor-like kinase 1 gene (ACVRL1). The patient was finally diagnosed with HHT according to the Curaçao diagnostic criteria eight years after the diagnosis of PAH. This case supports previous reports indicating that signs of PAH can be the first manifestation of disease in ACVRL1 mutation carriers.
Introduction
Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Rendu-Weber disease, is an autosomal dominant disorder characterized by epistaxis, telangiectasia and arteriovenous malformations (AVMs), particularly in the lungs, liver and brain (1, 2) . Pulmonary hypertension (PH) with HHT is a very rare pulmonary manifestation that can be severe. Recently, the activin receptor-like kinase 1 gene (ACVRL1, also known as ALK1), endoglin gene (ENG) and mothers against decapentaplegic homolog 4 gene (MADH4) have been identified to be causative for HHT. Although the above genes are associated with the transforming growth factor beta (TGF-beta) superfamily signaling pathway, which is essential for maintaining vascular integrity (3) (4) (5) , the relationships between these genes and the onset of PH, particularly pulmonary arterial hypertension (PAH), in HHT patients remain unknown. The incidence of HHT in the Japanese population has been reported to be 1 in 5,000-8,000 (6) . In this report, the number of HHT patients with ENG mutations was roughly twice as many as that with ACVRL1 mutations in Japan (7) . We herein describe the case of a young Japanese girl with HHT and a mutation in ACVRL1 who was diagnosed with PAH.
Case Report
A 17-year-old Japanese girl with no previous medical history was referred to our hospital for an evaluation of exertional dyspnea. She had a seven-month history of exertional dyspnea and exhibited a New York Heart Association functional (NYHA) class III status on admission. A physical examination revealed a blood pressure of 82/56 mmHg, a pulse rate of 56 beats/min, a respiratory rate of 16 breaths/ min, a pulse oximetry of 96% on room air and a body temperature of 36.5 . A cardiopulmonary examination revealed clear lung fields with an accentuated pulmonic second heart Department of Respirology, Graduate School of Medicine, Chiba University, Japan, Division of Pulmonary Circulation, Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Japan and Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center Research Institute, Japan (C)
sound. Mucosal and skin examinations demonstrated no areas of telangiectasia on the skin, buccal mucosa or tongue. Chest radiography showed prominent hilar pulmonary arteries, with a cardiothoracic ratio of 48.6% (Fig. 1 ). An electrocardiogram disclosed a normal sinus rhythm, with right axis deviation and inverted T waves in V1-4. A transthoracic echocardiogram demonstrated a normal left ventricle size and function, a dilated right ventricle, severe tricuspid regurgitation and an estimated right ventricular systolic pressure of 110 mmHg with no obvious shunts. Pulmonary function testing showed normal forced vital capacity (FVC), forced expiratory volume (FEV)1 and FEV1/FVC values, with a decreased diffusion capacity of the lungs for carbon monoxide (69.7% of the predicted value). No ventilation-perfusion mismatch was detected on a lung scintigraphic examination.
Right heart catheterization revealed severe precapillary PH, with a mean pulmonary artery pressure of 48 mmHg (88/28), pulmonary arterial wedge pressure of 4 mmHg, pulmonary vascular resistance (PVR) of 11.8 WU and cardiac index of 2.4 L/min/m 2 ( Table 1) . No O2 step-up was found. A pulmonary angiogram showed no evidence of acute or chronic pulmonary emboli or AVMs. The patient was diagnosed with PAH based on these clinical and radiological findings. Laboratory testing was negative for human immunodeficiency virus, autoimmune diseases, hepatitis and hypercoagulability ( Table 2 ). The patient had not previously used medical agents known to possibly cause PH. Therefore, her PAH was considered to be idiopathic or heritable at that time. In detail questioning of the patient's family history revealed that her mother and grandmother on her mother's side had been diagnosed with HHT. A clinical genetic mutation analysis was performed, which revealed a mutation in ACVRL1 (c.1196G > T, p.Trp399Leu) and negative findings for bone morphogenetic protein receptor 2. This genetic study was approved by the ethics committee of Chiba University Hospital (approval number: 85). Hence, the patient was diagnosed with heritable PAH.
We subsequently administered therapy with oral beraprost sodium, warfarin and oxygen. However, the patient developed frequent epistaxis and required the cessation of warfarin. Additionally, since another transthoracic echocardiogram showed a high estimated right ventricular systolic pressure (98 mmHg), treatment with bosentan was initiated in substitution for beraprost sodium. Thereafter, therapy with tadalafil and diuretics was commenced, as a high level of brain natriuretic peptide was continuously observed. Frequent episodes of epistaxis with anemia (Hb: 5.8 mg/dL) requiring repetitive blood transfusions were noted, and an otolaryngological examination revealed a few vasodilatory lesions primarily scattered on the inferior nasal concha bilaterally (Fig. 2) . These clinical features satisfied the Curaçao diagnostic criteria for HHT eight years after the diagnosis of PAH. On the other hand, no malformations of the hepatic arterial or venous systems were suggested on Doppler ultrasonography or abdominal angio-CT. Although few differences were observed on chest radiography and electrocardiography compared to the findings noted at admission (Fig. 3) , the most recent follow-up right heart catheterization examination showed worsening of PH [mean pulmonary artery pressure: 55 mmHg (87/35), PVR: 11.4 WU and cardiac index: 2.5 L/min/m 2 ] ( Table 1 ). The administration of continuous intravenous epoprostenol was difficult due to repeated episodes of epistaxis.
Discussion
We herein presented a case of PAH in an HHT patient carrying an ACVRL1 gene mutation. The first manifestation in the present case was PH as a form of PAH identified eight years before the diagnosis of HHT, whereas spontaneous recurrent epistaxis from telangiectasia in the nasal mucosa is commonly the first manifestation in HHT patients (> 90%) (1) .
The development of PH in HHT patients can occur via two different mechanisms: PH associated with an increased cardiac output and heart failure due to systemic AVMs, mostly in the liver (8) , and, less frequently, precapillary PH as a form of PAH (3). The former mechanism involves hyperdynamic hemodynamics resulting from arteriovenous shunting, portovenous shunting or both. Garcia-Tsao and colleagues reported that eight of 19 patients with HHT and liver involvement exhibited an elevated cardiac output and pulmonary capillary wedge pressure (9) . As for patients with PH associated with systemic AVMs, right heart catheteriza- (A) (B)
tion typically shows a high cardiac output, elevated pulmonary capillary wedge pressure and normal PVR (9) (10) (11) . On the other hand, the latter mechanism of PH is a form of PAH, which has been increasingly recognized to be a complication of HHT (12) (13) (14) . Right heart catheterization in PAH patients with HHT shows an increased mean pulmonary artery pressure with a low cardiac output, normal pulmonary capillary wedge pressure and high PVR (10, 11, 13) . Based on the findings of right heart catheterization, the present patient was diagnosed with precapillary PH (i.e., PAH), and no malformations of the hepatic arterial or venous systems were detected on Doppler ultrasonography or systemic CT angiography.
Mutations in three genes, ACVRL1, ENG and MADH4, have been implicated in the pathogenesis of HHT (3) (4) (5) . All three of these genes code for receptor or signal molecules of the TGF-beta superfamily signaling pathway. The ACVRL1 gene, which was detected in the present case, codes for ALK1 encoding TGF-beta type I receptors (15) . The TGFbeta receptor complex modulates angiogenesis and cell differentiation in systemic endothelial cells. Defects in TGFbeta signaling may explain abnormalities in angiogenesis in patients with HHT. In the present case, a mutation of Trp 399Leu in exon8 (a missense mutation in the kinase domain) of the ACVRL1 gene was detected. The amino acid substitution at the same position, p.Trp399Ser (c.1196G > C), was previously reported in a PAH patient with HHT (10). The reported case was a 29-year-old woman who presented with epistaxis, telangiectasia and PAH without AVMs, similar to the present patient, although the first onset of PAH and/or HHT was not described. Although the literature regarding the onset of PAH with HHT in patients carrying ACVRL1 mutations is limited, 375 variants in ACVRL1 (16) and 27 different ACVRL1 exonic mutations in the context of PAH (4) have been reported. A genomic study of Japanese pediatric patients with PAH identified five patients carrying an ACVRL1 mutation who were diagnosed with PAH without any signs of HHT (17) . Among the nine patients with PAH carrying an ACVRL1 mutation in the French PAH Network, four in three families had a diagnosis of PAH preceding HHT diagnosis, one had a diagnosis of HHT preceding a PAH diagnosis, one was diagnosed with HHT and PAH simultaneously and the remaining three patients had PAH only (4) . Although the relationships between ACVRL1 gene mutations and the onset of PAH in HHT patients remain unclear, the present and previous cases indicate that signs of PAH can be the first manifestation of disease in ACVRL1 mutation carriers (10, 17) .
The clinical diagnosis of HHT is generally based on the Curaçao criteria. The disease is considered when at least three of the following four criteria are present: epistaxis, telangiectasia, visceral vascular anomalies and/or a family history of the disease (2). The present patient had epistaxis, telangiectasia on the nasal mucosa and a family history of HHT. A pedigree chart is presented in Fig. 4 . Her mother developed refractory epistaxis starting at 18 years of age, which subsequently worsened, requiring nasal dermoplasty at 48 years of age. The patient's grandmother on her mother's side had been diagnosed with HHT due to recurrent epistaxis and bleeding from gastrointestinal telangiectasia. Four additional relatives also experienced episodes of recurrent epistaxis. On the other hand, no relatives developed dyspnea indicating the existence of PH. Unfortunately, we were unable to perform screening for PH or AVMs in the patient's relatives. In general, there is great variability in clinical manifestations among members of a lineage, and it is therefore unlikely that mutations alone cause PH. This finding reinforces the hypothesis that an additional genetic or environmental hit is required to trigger the development of pulmonary vascular disease (18) (19) (20) . Girerd and col- leagues reported a female predominance in ACVRL1 mutation carriers who develop PAH (4) . Although the authors speculated that this finding may reflect the effects of female sex hormones on vascular remodeling, this issue remains unclear.
Although the literature regarding the specific treatment of PAH with HHT is limited to sporadic reports of clinical cases, modern therapies for PAH, such as prostacyclin, endothelin receptor antagonists and phosphodiesterase-5 inhibitors, have been used in such patients. In the present case, the PAH gradually worsened after diagnosis despite the application of upfront combination therapy with PAH-targeted drugs. Additionally, the use of continuous intravenous epoprostenol for severe PH was not possible in the present case due to the patient's frequent episodes of epistaxis requiring blood transfusions. PAH patients with ACVRL1 mutations are relatively younger at the time of PAH diagnosis and tend to exhibit a worse prognosis. It has also been suggested that disease progression is more rapid in ACVRL1 mutation carriers than in non-carriers and that responsiveness to vasodilators is poor among patients with PAH carrying ACVRL1 mutations (4).
We herein described the case of a 17-year-old Japanese girl diagnosed with PAH in HHT and an ACVRL1 mutation. Because PAH can be the first manifestation of disease in ACVRL1 mutation carriers, physicians must be careful when diagnosing patients with PAH. Obtaining a detailed family history and conducting a systemic search for the clinical features of HHT is required.
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